Personalis Acquisition Price Warranted by Growth Prospects, Needham Says

MT Newswires Live03:33

Personalis' (PSNL) agreed acquisition price from Tempus AI (TEM) is supported by strong growth in its NeXT Personal platform, Medicare reimbursement wins and a large minimal residual disease market opportunity, Needham said in a Monday note.

The brokerage said Tempus agreed to acquire Personalis for $16.25 per share in stock, valuing the company at about $1.5 billion, with Tempus paying about 15.5 times Personalis' estimated 2027 enterprise value-to-sales multiple. Needham said the valuation is well above that of its small- and mid-cap growth peers but is warranted given the company's growth outlook.

Needham also said competing bids and antitrust concerns are unlikely, citing reports that multiple bidders pursued Personalis and the companies' limited share of the minimal residual disease market.

The transaction is expected to close in late 2026 or early 2027.

Needham downgraded Personalis to hold from buy and withdrew its $17 price target.

Shares of Personalis were down 14% in Monday trading.

Price: 13.24, Change: -2.15, Percent Change: -13.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2653439392?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 03:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653439392","market":"hk","top_or_hot":-1,"title":"Personalis Acquisition Price Warranted by Growth Prospects, Needham Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PSNL\">Personalis</a>' (PSNL) agreed acquisition price from <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) is supported by strong growth in its NeXT Personal platform, Medicare reimbursement wins and a large minimal residual disease market opportunity, Needham said in a Monday note.</p><p>The brokerage said Tempus agreed to acquire Personalis for $16.25 per share in stock, valuing the company at about $1.5 billion, with Tempus paying about 15.5 times Personalis' estimated 2027 enterprise value-to-sales multiple. Needham said the valuation is well above that of its small- and mid-cap growth peers but is warranted given the company's growth outlook.</p><p>Needham also said competing bids and antitrust concerns are unlikely, citing reports that multiple bidders pursued Personalis and the companies' limited share of the minimal residual disease market.</p><p>The transaction is expected to close in late 2026 or early 2027.</p><p>Needham downgraded Personalis to hold from buy and withdrew its $17 price target.</p><p>Shares of Personalis were down 14% in Monday trading.</p><p>Price: 13.24, Change: -2.15, Percent Change: -13.97</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Personalis Acquisition Price Warranted by Growth Prospects, Needham Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPersonalis Acquisition Price Warranted by Growth Prospects, Needham Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-21 03:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PSNL\">Personalis</a>' (PSNL) agreed acquisition price from <a href=\"https://laohu8.com/S/TEM\">Tempus AI</a> (TEM) is supported by strong growth in its NeXT Personal platform, Medicare reimbursement wins and a large minimal residual disease market opportunity, Needham said in a Monday note.</p><p>The brokerage said Tempus agreed to acquire Personalis for $16.25 per share in stock, valuing the company at about $1.5 billion, with Tempus paying about 15.5 times Personalis' estimated 2027 enterprise value-to-sales multiple. Needham said the valuation is well above that of its small- and mid-cap growth peers but is warranted given the company's growth outlook.</p><p>Needham also said competing bids and antitrust concerns are unlikely, citing reports that multiple bidders pursued Personalis and the companies' limited share of the minimal residual disease market.</p><p>The transaction is expected to close in late 2026 or early 2027.</p><p>Needham downgraded Personalis to hold from buy and withdrew its $17 price target.</p><p>Shares of Personalis were down 14% in Monday trading.</p><p>Price: 13.24, Change: -2.15, Percent Change: -13.97</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653439392","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653439392","pubTimestamp":1784576027,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Personalis'  agreed acquisition price from Tempus AI  is supported by strong growth in its NeXT Personal platform, Medicare reimbursement wins and a large minimal residual disease market opportunity, Needham said in a Monday note.The brokerage said Tempus agreed to acquire Personalis for $16.25 per share in stock, valuing the company at about $1.5 billion, with Tempus paying about 15.5 times Personalis' estimated 2027 enterprise value-to-sales multiple. Needham said the valuation is well above that of its small- and mid-cap growth peers but is warranted given the company's growth outlook.Needham also said competing bids and antitrust concerns are unlikely, citing reports that multiple bidders pursued Personalis and the companies' limited share of the minimal residual disease market.The transaction is expected to close in late 2026 or early 2027.Needham downgraded Personalis to hold from buy and withdrew its $17 price target.Shares of Personalis were down 14% in Monday trading.Price: 13","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","HEAL":"Global X HealthTech ETF","TEM":"Tempus AI","TEMT":"2倍做多TEM ETF-Tradr","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4613":"AI应用软件","PSNL":"Personalis","BK4611":"AI医疗","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","ARKG":"ARK Genomic Revolution ETF"},"translate_title":"Needham 表示，增长前景证明了 Personalis 的收购价格","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HEAL":0.6,"PSNL":1.97,"ARKG":0.6,"TEM":1.9,"TEMT":0.6},"content_text":"Personalis' (PSNL) agreed acquisition price from Tempus AI (TEM) is supported by strong growth in its NeXT Personal platform, Medicare reimbursement wins and a large minimal residual disease market opportunity, Needham said in a Monday note.The brokerage said Tempus agreed to acquire Personalis for $16.25 per share in stock, valuing the company at about $1.5 billion, with Tempus paying about 15.5 times Personalis' estimated 2027 enterprise value-to-sales multiple. Needham said the valuation is well above that of its small- and mid-cap growth peers but is warranted given the company's growth outlook.Needham also said competing bids and antitrust concerns are unlikely, citing reports that multiple bidders pursued Personalis and the companies' limited share of the minimal residual disease market.The transaction is expected to close in late 2026 or early 2027.Needham downgraded Personalis to hold from buy and withdrew its $17 price target.Shares of Personalis were down 14% in Monday trading.Price: 13.24, Change: -2.15, Percent Change: -13.97","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2653439392","isCrawlerRequest":true}